Analyzing Centene Corporation's Stock Performance

Large-cap Health Care company Centene has moved -2.7% so far today on a volume of 3,880,935, compared to its average of 3,509,336. In contrast, the S&P 500 index moved 0.0%.

Centene trades -24.97% away from its average analyst target price of $88.49 per share. The 17 analysts following the stock have set target prices ranging from $76.0 to $110.0, and on average have given Centene a rating of buy.

If you are considering an investment in CNC, you'll want to know the following:

  • Centene's current price is -8.6% below its Graham number of $72.62, which implies the stock has a margin of safety

  • Centene has moved 0.6% over the last year, and the S&P 500 logged a change of 25.7%

  • Based on its trailing earnings per share of 5.07, Centene has a trailing 12 month Price to Earnings (P/E) ratio of 13.1 while the S&P 500 average is 27.65

  • CNC has a forward P/E ratio of 8.7 based on its forward 12 month price to earnings (EPS) of $7.6 per share

  • The company has a price to earnings growth (PEG) ratio of 0.8 — a number near or below 1 signifying that Centene is fairly valued compared to its estimated growth potential

  • Its Price to Book (P/B) ratio is 1.32 compared to its sector average of 3.61

  • Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

  • Based in Saint Louis, the company has 59,900 full time employees and a market cap of $35.43 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.